DiaMedica Therapeutics Inc. announces the publication of a peer-reviewed article detailing DM199's mechanism of action for treating acute ischemic stroke. The study highlights DM199's potential benefits in enhancing blood flow and preventing stroke recurrence through multiple biological pathways.
Company Information
Company
DiaMedica Therapeutics
Location
301 CARLSON PARKWAY
Minneapolis, Minnesota, United States
About
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), is a clinical-stage biopharmaceutical company that is focused on developing novel treatments where there is significant unmet clinical need or where no current therapies are available, with the focus on acute ischemic stroke and preeclampsia.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment DiaMedica Therapeutics ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.